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Abstract
Background: The intranasal (IN) route for rapid drug administration in patients with
brain disorders, including status epilepticus, has been investigated. Status epilepticus
is an emergency, and the IN route offers a valuable alternative to other routes, espe-
cially when these fail.
Objectives: To compare IN versus IV midazolam (MDZ) at the same dosage (0.2 mg/kg)
for controlling status epilepticus in dogs.
Abbreviations: BBB, blood-brain barrier; IN, intranasal; MAD, mucosal atomization device; MDZ, midazolam.
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Animals: Client-owned dogs (n = 44) with idiopathic epilepsy, structural epilepsy, or
epilepsy of unknown origin manifesting as status epilepticus.
Methods: Randomized parallel group clinical trial. Patients were randomly allocated to
the IN-MDZ (n = 21) or IV-MDZ (n = 23) group. Number of successfully treated cases
(defined as seizure cessation within 5 minutes and lasting for ≥10 minutes), seizure ces-
sation time, and adverse effects were recorded. Comparisons were performed using the
Fisher's exact and Wilcoxon rank sum tests with statistical significance set at α < .05.
Results: IN-MDZ and IV-MDZ successfully stopped status epilepticus in 76% and
61% of cases, respectively (P = .34). The median seizure cessation time was 33 and
64 seconds for IN-MDZ and IV-MDZ, respectively (P = .63). When the time to place
an IV catheter was taken into account, IN-MDZ (100 seconds) was superior (P = .04)
to IV-MDZ (270 seconds). Sedation and ataxia were seen in 88% and 79% of the dogs
treated with IN-MDZ and IV-MDZ, respectively.
Conclusions and Clinical Importance: Both routes are quick, safe, and effective for
controlling status epilepticus. However, the IN route demonstrated superiority when
the time needed to place an IV catheter was taken into account.
K E YWORD S
benzodiazepines, canine, emergency, epilepsy, nasal
1 | INTRODUCTION
Status epilepticus is an emergency that requires rapid and effective
delivery of anti-seizure drugs. Rapid treatment is crucial to avoid pri-
mary and secondary brain injury and systemic complications. Because
of the anatomical and physiological properties of the nasal cavity as
well as its potential to circumvent the blood-brain barrier (BBB), the
intranasal (IN) route might offer an advantageous and novel way to
directly and quickly deliver drugs to the brain to treat various disor-
ders.1-7 Intranasal drug delivery has been widely investigated for anes-
thetic purposes, and experimental studies have reported that it can be
effectively used for analgesia (IN-fentanyl),8 sedation (IN-xylazine,9
IN-medetomidine/ketamine,10 IN-ketamine,11,12) and sedation and opi-
oid reversal (IN-atipamezole/IN-naltrexone).13
Benzodiazepines (eg, midazolam [MDZ]), are used commonly as a
first-line management option for status epilepticus in humans and
dogs.14-23 Midazolam, a water-soluble benzodiazepine, is considered an
effective and safe anti-seizure drug when administered by the IN, IV, or
IM routes.15,18,20-24 Intranasal MDZ can be useful or even life-saving,
especially when IV access is not available.15,25 Intranasal MDZ has been
reported to be an effective and safe choice as a sedative drug in children
undergoing diagnostic and minor surgical procedures.26-29 It also has been
shown to suppress epileptic spike activity on electroencephalograms of
epileptic children.30 Based on clinical trials, which evaluated the efficacy
of IN-MDZ, it was concluded that IN-MDZ was effective and safe for ter-
minating status epilepticus in humans and that it can be used not only by
clinicians in the hospital environment but also by families at home.22,31
It was recently demonstrated that IN-MDZ was effective and safe as
well as superior to rectally administered diazepam for the management
of status epilepticus in dogs with idiopathic epilepsy, structural epilepsy,
or epilepsy of unknown origin.15 In the present study, we compared
MDZ given at the same dose but by different routes (IN or IV) for the
treatment of status epilepticus in dogs. Our aim was to provide further
evidence of the potential efficacy and safety of IN-MDZ in dogs with
status epilepticus and compare it to the gold standard of IV administra-
tion to evaluate if a significant difference existed between the 2 routes
in the time needed to terminate the epileptic seizures.
2 | MATERIALS AND METHODS
The methodology we used was similar to that of a previous trial of
IN-MDZ, which has been described previously.15 The current study was
an open-label randomized parallel group clinical trial including client-
owned dogs and approved by the enrolling universities' ethical commit-
tees. Owner information and consent forms for the study were com-
pleted. Dogs with status epilepticus manifesting generalized or focal
epileptic seizures with any type of motor activity (ie, tonic-clonic or myo-
clonic) caused by idiopathic epilepsy, structural epilepsy, or epilepsy of
unknown origin were included. Dogs with reactive seizures associated
with metabolic or toxic causes or dogs that had received any drugs
before 5 minutes of continuous epileptic seizure activity had passed
were excluded. Classification of epilepsy types, clinical signs, and diag-
nostic approach were based on the International Veterinary Epilepsy
Task Force consensus reports.32,33 In particular, for the diagnosis of idio-
pathic epilepsy, classification into 3 tiers of confidence was performed
based on history, signalment, and unremarkable interictal neurological
examination, blood tests, brain magnetic resonance imaging, and
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cerebrospinal fluid analysis.33 Status epilepticus was defined as a contin-
uous epileptic seizure lasting more >5 minutes, or ≥2 discrete epileptic
seizures between which incomplete recovery of consciousness
occurred.32 Dogs that manifested status epilepticus were randomly
assigned to IN-MDZ or IV-MDZ groups, using randomized sealed enve-
lopes. Midazolam was administered at the same dosage for both routes
(ie, 0.2 mg/kg) after at least 5 minutes of continuous seizure activity. In
the dogs allocated to the IV-MDZ group, an IV catheter, if not already
present, was placed immediately. In the IN-MDZ group, an IV catheter
was placed after MDZ administration to provide IV access. All dogs were
treated and remained in a hospital environment for constant observation
and monitoring for at least 1 hour after benzodiazepine administration.
3 | OUTCOME ASSESSMENT
3.1 | Primary outcomes
The outcome measurements included:
1. “Seizure cessation” time, defined as the time between drug admin-
istration and seizure cessation.
2. “Seizure relapse” time, defined as the time between seizure cessa-
tion and the next seizure.
3. “Doctor-to-drug” time, defined as the time needed by the clinician
for preparation and administration of the drug. For the IN-MDZ
group, the “doctor-to-drug” time included the time needed for
preparation of the mucosal atomization device (MAD) and admin-
istration of the MDZ and, for the IV-MDZ group, the time needed
to place an IV catheter (if not placed previously) and for prepara-
tion and administration of the MDZ.
4. “Total seizure cessation time” included both the “doctor-to-drug”
and “seizure cessation time” in order to evaluate if the time needed
for the seizures to cease was affected by the preparation and admin-
istration of IN-MDZ or IV-MDZ and placement of an IV catheter.
Cases were considered successful if “seizure cessation time” was
<5 minutes after drug administration and the “seizure relapse time”
TABLE 1 Details of signalment, clinical and disease characteristics in each group
Groups IN-MDZ IV-MDZ
Breed Crossbreed (22%), Border Collie (15%), Beagle (9%),
GSD (9%), Golden Retriever (9%), Labrador
Retriever (4%), Chihuahua (4%), Australian
Shepherd Dog (4%), German Shorthaired Pointer
(4%), Pincher (4%), Irish Setter (4%), Siberian
Husky (4%), Pitbull (4%), Cane Corso (4%)
Crossbreed (32%), CKCS (9%), GSD (9%), Border
Collie (9%), Labrador Retriever (9%), Dogo
Argentino (4%), Dachshund (4%), Poodle (4%),
Shih Tzu (4%), Pekingese (4%), Pug (4%),
Siberian Husky (4%), English Bulldog (4%)
Age, median (range), y 6 (0.6-12) 5 (0.3-12.6)
Sex Seven intact and 5 neutered males (57%) and 3
intact and 6 neutered females (43%)
Eight intact and 7 neutered males (65%) and 2
intact and 6 neutered females (35%)
Duration of epileptic seizures
prior to trial initiation,
median (range), s
480 (310-3600) 510 (302-14 400)
Epilepsy etiological
classification
Twelve dogs (57%) with idiopathic epilepsy, 6 dogs
(29%) with structural epilepsy (neoplasia, 1 dog;
MUO, 3 dogs; ischemic encephalopathy, 1 dog;
hematoma, 1 dog), and 3 dogs (14%) with
epilepsy of unknown origin
Thirteen dogs (56%) with idiopathic epilepsy, 8
dogs (35%) with structural epilepsy (neoplasia,
2 dogs; trauma, 1 dog; MUO, 4 dogs;
congenital hydrocephalus, 1 dog), and 2 dogs
(9%) with epilepsy of unknown origin
Epileptic seizure type
classification
One dog (5%) with focal orofacial epileptic
seizures; 20 dogs (95%) with generalized tonic/
clonic epileptic seizures
Twenty-three dogs (100%) with generalized
tonic/clonic epileptic seizures
Chronic/maintenance AEDs Eleven dogs (53%) were not receiving chronic
antiepileptic medication; the remaining dogs
were receiving phenobarbital monotherapy (5
dogs; 25%), imepitoin monotherapy (2 dogs;
10%), levetiracetam monotherapy (1 dog; 4%),
phenobarbital/potassium bromide combination
treatment (1 dog; 4%), and phenobarbital/
potassium bromide/levetiracetam/clonazepam
combination treatment (1 dog; 4%)
Fourteen dogs (62%) were not receiving chronic
antiepileptic medication; the remaining dogs
were receiving phenobarbital monotherapy (4
dogs; 17%), levetiracetam monotherapy (2
dogs; 9%), phenobarbital/potassium bromide
combination therapy (1 dog; 4%),
phenobarbital/potassium bromide/
levetiracetam/zonisamide combination
treatment (1 dog; 4%), and phenobarbital/
potassium bromide/levetiracetam/clonazepam
combination treatment (1 dog; 4%)
Cluster epilepsy (before
occurrence of status
epilepticus)
Twelve dogs (60%) Seven dogs (47%)
Abbreviations: AEDs, antiepileptic drugs; CKCS, Cavalier King Charles Spaniel; GSD, German Shepherd Dog; IN, intranasal; MDZ, midazolam; MUO,
meningoencephalitis of unknown origin.
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was >10 minutes.15 For the unsuccessful cases, the protocol was no
longer applicable and additional anti-seizure drugs could be given as
directed by the clinician in charge.
3.2 | Secondary outcomes
The outcome measurements included:
1. Complications and adverse effects. Heart rate and rhythm, respira-
tory rate and pattern, blood pressure (by use of Doppler) and oxy-
gen saturation (by use of pulse oximetry) were measured 5 (T5) and
10 (T10) minutes after drug administration and reported if abnor-
mal. Any other unusual events or adverse effects, such as dyspnea,
sneezing, vomiting, as well as sedation or ataxia that occurred
within 60 minutes were recorded.
2. Difficulties in administration. Any concerns were recorded by the
clinician in charge, with examples including but not limited to diffi-
culties in delivering the MAD into the nostrils or placing an IV
catheter in a seizuring dog.
3. Further information, such as history of antiepileptic drugs and
duration of dogs' seizure activity before inclusion in the trial, was
recorded.
3.3 | Statistical analysis
As in a previous trial,15 the primary outcomes evaluated were the
number of successful cases in each group and seizure cessation times.
Statistical analysis was conducted using the statistical software R (ver-
sion 3.5.2). Significance was set at α ≤ .05. The number of successfully
treated cases per group was compared between the 2 groups (IV or
IN) using a Fisher's exact test. The remaining outcomes (“seizure ces-
sation” time, “doctor-to-drug” time, and “total seizure cessation” time)
were compared using a Wilcoxon rank sum test. Continuous variables
are reported as median and range.
4 | RESULTS
4.1 | Signalment and baseline characteristics of study
subjects and disease characterization
Details of signalment, clinical findings, and disease characteristics of
the included cases are provided in Table 1.
4.2 | Primary and secondary outcomes
Forty-nine dogs initially were included but 5 were excluded because they
were diagnosed with reactive seizures caused by intoxication. Status
epilepticus was terminated within 5 minutes by IN-MDZ (n = 21) and
IV-MDZ (n = 23) in 76% and 61% of cases, respectively. This difference
was not statistically significant (P = .34). Seizure cessation time was
not significantly different (IN-MDZ [median, 33 seconds] compared to
IV-MDZ [median, 64.5 seconds]; P = .63). However, when the time to
place an IV catheter and prepare the medication also was considered (ie,
total seizure cessation time), IN-MDZ (median, 100 seconds) was superior
(P = .04) to IV-MDZ (median, 270 seconds). For dogs with idiopathic epi-
lepsy, status epilepticus was terminated in 83% and 69% of the cases by
IN-MDZ and IV-MDZ, respectively (P = .64). The seizure cessation time
also was not significantly different (IN-MDZ [median, 27 seconds] com-
pared to IV-MDZ [median, 78 seconds]; P = .07). However, by adding the
time needed to place an IV catheter and prepare the medication (total sei-
zure cessation time), IN-MDZ (median, 66 seconds) was superior (P = .02)
to IV-MDZ (median, 314 seconds). In 21% of the successful IV-MDZ
cases, an IV catheter already had been placed before trial initiation. During
treatment, no serious adverse effects, apart from sedation and ataxia, and
no important difficulties in preparing and administering the medication in
either group were reported. Details about the primary and secondary out-
comes for each group are provided in Table 2.
5 | DISCUSSION
Our results indicate that both IN and IV administration of MDZ are
effective and safe methods for the management of status epilepticus in
dogs. In our study, seizure cessation time for IN-MDZ compared to
IV-MDZ, at the dosage of 0.2 mg/kg, was not significantly different.
However, IN-MDZ was superior to IV-MDZ in terminating the epileptic
seizures when the time to place an IV catheter was considered. It could
be hypothesized that the IN route is a favorable alternative to the IV
route, especially in cases in which establishing an IV access is not imme-
diately possible, difficult, or time-consuming. This could be particularly
beneficial for status epilepticus because the prognosis is time-dependent
(ie, prolonged seizures are associated with worse outcome and treatment
resistance and require immediate management).34 Many clinical and
pharmacokinetic studies have shown successful results after IN adminis-
tration of benzodiazepines, in particular MDZ, in epileptic and normal
humans as well as in animals.15,22,25,31,35-49 Studies in epileptic humans
that compared IN to IV administration of benzodiazepines showed that
both routes were effective for seizure cessation.22,31,50 Specifically, IN-
MDZ was as safe and effective as IV diazepam but, if the time to place
an IV catheter was not taken into account, seizures were controlled
more quickly with IV diazepam. In our study, we found that IN-MDZ
was quicker than IV-MDZ, and the difference was significant when the
time to place an IV catheter was taken into account. Lastly, a meta-
analysis in human patients concluded that although there was minimal
difference in the time interval from drug administration to clinical seizure
cessation, which was shorter for diazepam by any route than for non-IV
MDZ by any route, this difference was not clinically relevant.51
Increasing interest in IN drug administration as a therapeutic option
for brain and systemic diseases derives from the particular anatomical,
physiological, and histological characteristics of the nasal cavity. Intranasal
administration provides an opportunity for rapid systemic drug absorp-
tion and rapid onset of action as well as different and advantageous path-
ways through which the drug can reach the brain.3,6,52-57 The canine
nasal cavity is divided by the nasal septum into 2 symmetric airways, each
including the nasal vestibule, respiratory and olfactory regions.58 The
nasal vestibule has limited vascularization and permeability, which leads
CHARALAMBOUS ET AL. 5
to poor absorption of substances such as drugs.7,58,59 In contrast,
the respiratory and olfactory regions have high vascularization and good
permeability and, therefore, are the main sites of drug absorption.7,58
Although lipid-soluble small molecules can be absorbed more easily from
the nasal cavity, many drugs targeting the brain are water-soluble small
molecules or large molecules (>400 Da) that cannot freely pass through
various mucosal barriers of the body including the nasal mucosa.
Midazolam is water-soluble (marketed solution pH = 3.5) but, after IN
administration, becomes lipid-soluble (nasal cavity pH = 5.5-6.51,60), and
as a result it can cross the nasal mucosa and pass into the brain with a
rapid onset of action.25,61,62 After absorption, some amount of the drug
will undergo clearance and drainage by the systemic circulation and
nasal lymphatic vessels, and might not reach the brain.52 The remaining
amount passes into the circulation and reaches the BBB without being
subject to the first-pass hepatic metabolism, which can enhance the
drug's bioavailability.22,25,62-67
The BBB is an essential factor limiting the development of new drugs
targeting the brain because it can restrict the influx of drugs into the
brain. All large molecules (ie, >400 Da) and >98% of small molecules can-
not penetrate the BBB6,54 and therefore cannot achieve adequate thera-
peutic concentrations in the brain after IV or PO administration.68 Only a
few lipid-soluble small molecules (<400 Da; e.g., benzodiazepines, pheno-
barbital) can penetrate the BBB by lipid-mediated free diffusion, treating
specific disorders such as epilepsy.69 Recent studies, however, showed
that some proteins,56,57,70 peptides,71,72 and oligonucleotides73,74 actually
could reach the brain after IN administration, which supports the fact that
these molecules potentially avoided the BBB. Bypassing the BBB, drugs
that might not be able to enter the brain could benefit from IN adminis-
tration and might require lower doses to be effective with fewer adverse
effects.75,76 This could be a reason why in our study administration
0.2 mg/kg of MDZ IN resulted in an overall higher number of successfully
treated cases compared to IV administration, although there was no sta-
tistically significant difference. In addition, bypassing the BBB might be
beneficial for dogs with drug-resistant idiopathic epilepsy, because the
BBB plays an important role in developing antiepileptic drug resistance
(ie, because of overexpression of drug transporters such as P-glycoprotein
and multidrug-resistance-associated protein).77-79 Some molecules can
avoid the BBB, enter the brain, and then be distributed to other brain
areas from the point of entry, via the olfactory (within olfactory epithe-
lium) and trigeminal (within respiratory epithelium) nerves.52,56,57,80 Vari-
ous mechanisms of transport via these nerve pathways have been
described.56,57,81 Final distribution of the drug after brain entry points at
the level of the olfactory bulb (via the olfactory nerve and nasal epithe-
lium) and the brainstem (via the trigeminal nerve) to other areas of the
brain is likely established by intracellular and extracellular transport
mechanisms.82-85
Apart from the properties and advantages that the IN route offers to
the administration of drugs that target the brain, another important
aspect is the formulation and delivery method of the drug (ie, the nasal
device). These factors can influence uptake of the drug by the brain. In
our trial, similar to a previous study,15 we used the MAD used in
humans, to deliver the medication into the nasal cavity. This MAD is a
type of a spray device that can be used like a syringe and delivers the
drug as a very fine mist of 30-100 μm particles, enhancing the drug's
absorption and bioavailability.86,87 In veterinary medicine, because the
IN drug delivery route has not yet been well established nor widely
investigated, no species- or breed-specific nasal administration devices
are available. For epilepsy in dogs, in particular, a device should be
designed that can contain an MDZ solution and provide quick and
advanced delivery into the entire nasal cavity of the dog. Such a develop-
ment might further enhance the efficacy of IN-MDZ in cases of status
epilepticus. With regard to the drug, in order to choose the most appro-
priate formulation, the physiological and chemical properties of the drug
as well as the disease that is targeted should be taken into consideration.
In our study and the previous15 clinical study, the MDZ solution
marketed for IN administration was used and showed satisfactory
results. Lastly, appropriate training of individuals, and in particular pet
owners, on how to correctly prepare and administer the IN drug is crucial
for achieving the desirable results.
Our study had some limitations that could have adversely influenced
the number of successfully treated cases in both groups. In particular, the
underlying cause of the seizures could play a role in the response of the
affected dogs to MDZ. Epileptic seizures related to meningoencephalitis
of unknown origin, and focal epileptic seizures are negative prognostic fac-
tors for status epilepticus in dogs.88 Similarly to a previous trial,15 all cases
of meningoencephalitis of unknown origin and the 1 dog with focal epilep-
tic seizures were unsuccessfully treated, although the small number of
dogs in these categories precludes definite conclusions. Lastly, time-
dependent drug-resistant status epilepticus has been reported.34 The anti-
convulsant potency of benzodiazepines can decrease by 20-fold within
30 minutes of continuous seizure activity.89 In our study, the dogs' median
duration of epileptic seizure activity before the inclusion in the trial was
8 and 8.5 minutes in the IN-MDZ and IV-MDZ groups, respectively. This
fact might have adversely affected the efficacy of MDZ in both groups
compared to a situation in which MDZ had been administered earlier
(ie, within 5 minutes), although a larger number of dogs would be neces-
sary to draw firm conclusions. However, the waiting period of at least
5 minutes before administering MDZ was crucial in our study because,
otherwise, it could be argued that the epileptic seizures ceased because
they might have been self-limiting (ie, inclusion of non-status epilepticus
cases) and not a consequence of the MDZ administration.
6 | CONCLUSION
Based on our study, both IN and IV MDZ are effective, quick, and safe
first-line medications for controlling status epilepticus in dogs. Consider-
ing that establishing IV access in a dog with status epilepticus might be
problematic or delay further treatment, IN-MDZ could be used as a first-
line option, before IV access, for the treatment of status epilepticus in
dogs either at the clinic or by owners at home. Despite some consider-
ations with regard to a drug's absorption and delivery to the brain, the
IN route offers several potential advantages. These include rapid use and
onset of action, non-invasive and easy administration, a safe and effec-
tive method directly targeting the brain, and the ability to overcome the
BBB. Further preclinical and clinical studies (including a larger number of
6 CHARALAMBOUS ET AL.
subjects and different devices and drug dosages) focusing on this promis-
ing route should be performed to establish this therapeutic route for var-
ious brain disorders in dogs.
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